IKKγ NBD Inhibitory Peptide TFA

Name: IKKγ NBD Inhibitory Peptide TFA
Brand: MedChemExpress
SKU: HY-P1847A
Rating: 4.5 (1 reviews)

Cat. No.: HY-P1847A Purity: 99.31%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

IKKγ NBD Inhibitory Peptide TFA is a highly specific inhibitor NF-κB inhibitor. IKKγ NBD Inhibitory Peptide TFA acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide TFA could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

IKKγ NBD Inhibitory Peptide TFA Chemical Structure

Size	Price	Stock	Quantity
5 mg	USD 309	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 480	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 1400	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of IKKγ NBD Inhibitory Peptide TFA:

IKKγ NBD Inhibitory Peptide Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

In a canonical pathway, NF kappa B activation depends on the IKK complex activity, which is formed by three subunits (IKKκ and IKKβ and IKKγ/NEMO), thus the KKγ NBD Inhibitory Peptide TFA inhibits TNF-α-induced NF-kB activation^[2].
IKKγ NBD Inhibitory Peptide TFA (10 μM; 90 min) prevents Doxorubicin (HY-15142A)-induced (15 μM; 4 h) p65 phosphorylation in BT-474 cells^[2].
IKKγ NBD Inhibitory Peptide TFA (10 μM; 48 h) slightly inhibits BT-474 cell viability while it markedly enhances the effects on Doxorubicin^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

IKKγ NBD Inhibitory Peptide TFA (40 μg/4 μL; ICV; single dose; 2 h before MCAO) exhibits neuroprotective effect with reduction in DNA fragmentation, and its ischemic brain damage reduction mechanism be attributed to reduction in inflammation following ischemic injury in middle cerebral artery occlusion (MCAO) rats model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Adult male Sprague-Dawley rats (255 g) with middle cerebral artery occlusion (MCAO)^[3]
Dosage:	40 μg/4 μL
Administration:	Intracerebroventricular injection; 2 h before MCAO induction
Result:	Significantly reduced striatal IL-1b level in IKK-NBD peptide treated rats. Also resulted in reduced staining of microglial OX-42 and protection of BBB from ischemic insult.

Molecular Weight

3807.32

Formula

C₁₇₂H₂₆₀N₄₉F₃O₄₄S₁

Appearance

Solid

Color

White to off-white

Sequence Shortening

DRQIKIWFQNRRMKWKKTALDWSWLQTE

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H₂O

Peptide Solubility and Storage Guidelines:

1. Calculate the length of the peptide.

2. Calculate the overall charge of the entire peptide according to the following table:

	Contents	Assign value
Acidic amino acid	Asp (D), Glu (E), and the C-terminal -COOH.	-1
Basic amino acid	Arg (R), Lys (K), His (H), and the N-terminal -NH₂	+1
Neutral amino acid	Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q)	0

3. Recommended solution:

Overall charge of peptide	Details
Negative (<0)	1. Try to dissolve the peptide in water first. 2. If water fails, add NH₄OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (>0)	1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0)	1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.

Purity & Documentation

Purity: 99.31%

Select Batch:

Data Sheet (264 KB) SDS (252 KB)

COA (244 KB) LCMS (99 KB) Elemental Analysis Report (101 KB)

Handling Instructions (2659 KB)

References

[1]. Zhao J, et al. Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation. PLoS Biol. 2018 Jun 11;16(6):e2004663. [Content Brief]

[2]. Tapia MA, et al. Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle. 2007 Sep 15;6(18):2284-92. [Content Brief]

[3]. Desai A, et al. Neuroprotective potential of the NF-κB inhibitor peptide IKK-NBD in cerebral ischemia-reperfusion injury. Neurochem Int. 2010 Dec;57(8):876-83. [Content Brief]